- Home
- PPBT vs EVOK Comparison
PPBT vs EVOK Comparison
Compare PPBT & EVOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PPBT
- EVOK
- Stock Information
- Founded
- PPBT 2010
- EVOK 2007
- Country
- PPBT Israel
- EVOK United States
- Employees
- PPBT N/A
- EVOK N/A
- Industry
- PPBT Biotechnology: Pharmaceutical Preparations
- EVOK Biotechnology: Pharmaceutical Preparations
- Sector
- PPBT Health Care
- EVOK Health Care
- Exchange
- PPBT Nasdaq
- EVOK Nasdaq
- Market Cap
- PPBT 6.3M
- EVOK 4.2M
- IPO Year
- PPBT N/A
- EVOK 2013
- Fundamental
- Price
- PPBT $2.37
- EVOK $2.66
- Analyst Decision
- PPBT Strong Buy
- EVOK
- Analyst Count
- PPBT 1
- EVOK 0
- Target Price
- PPBT $33.00
- EVOK N/A
- AVG Volume (30 Days)
- PPBT 26.3K
- EVOK 19.4K
- Earning Date
- PPBT 08-15-2025
- EVOK 08-12-2025
- Dividend Yield
- PPBT N/A
- EVOK N/A
- EPS Growth
- PPBT N/A
- EVOK N/A
- EPS
- PPBT N/A
- EVOK N/A
- Revenue
- PPBT N/A
- EVOK $11,594,083.00
- Revenue This Year
- PPBT N/A
- EVOK $57.82
- Revenue Next Year
- PPBT N/A
- EVOK $59.12
- P/E Ratio
- PPBT N/A
- EVOK N/A
- Revenue Growth
- PPBT N/A
- EVOK 89.89
- 52 Week Low
- PPBT $2.00
- EVOK $1.94
- 52 Week High
- PPBT $13.95
- EVOK $12.32
- Technical
- Relative Strength Index (RSI)
- PPBT 42.59
- EVOK 40.87
- Support Level
- PPBT $2.25
- EVOK $2.50
- Resistance Level
- PPBT $2.45
- EVOK $2.84
- Average True Range (ATR)
- PPBT 0.13
- EVOK 0.22
- MACD
- PPBT -0.02
- EVOK -0.03
- Stochastic Oscillator
- PPBT 21.11
- EVOK 31.75
About PPBT Purple Biotech Ltd.
Purple Biotech Ltd is a clinical-stage company focused on advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, and to create treatments for people with cancer. Its oncology pipeline includes NT219: A dual inhibitor, small molecule that simultaneously targets Insulin Receptor Substrate 1 and 2 (IRS1/2) and Signal Transducer and Activator of Transcription (STAT3), two survival signal transduction pathways driving the development of cancer drug resistance. and CM24: is a humanized monoclonal antibody designed to block the interactions of Carcinoembryonic Antigen Related Cell Adhesion Molecule 1 (CEACAM1), a glycoprotein that plays a key role in immune regulation, cell adhesion, and tumor progression, CAPTN3.
About EVOK Evoke Pharma Inc.
Evoke Pharma Inc is a specialty pharmaceutical company focused on the development and commercialization of drugs to treat gastrointestinal, or GI, disorders, and diseases. The company's product Gimoti is an investigational metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women. Gimoti is a novel nasal spray formulation of metoclopramide designed to provide systemic delivery of the molecule through the nasal mucosa.